L C Huber

Summary

Affiliation: University Hospital
Country: Switzerland

Publications

  1. ncbi Trichostatin A prevents the accumulation of extracellular matrix in a mouse model of bleomycin-induced skin fibrosis
    Lars C Huber
    Center of Experimental Rheumatism, University Hospital Zurich, Gloriastrasse 25, 8091 Zurich, Switzerland
    Arthritis Rheum 56:2755-64. 2007
  2. ncbi Peripheral blood B lymphocytes derived from patients with idiopathic pulmonary arterial hypertension express a different RNA pattern compared with healthy controls: a cross sectional study
    Silvia Ulrich
    Department of Internal Medicine, Pulmonary Hypertension Clinic, University Hospital of Zurich, Zurich, Switzerland
    Respir Res 9:20. 2008
  3. ncbi Effects of a novel tyrosine kinase inhibitor in rheumatoid arthritis synovial fibroblasts
    L C Huber
    Center of Experimental Rheumatology, University Hospital Zurich, Gloriastrasse 25, CH 8091 Zurich, Switzerland
    Ann Rheum Dis 67:389-94. 2008
  4. ncbi Histone deacetylase/acetylase activity in total synovial tissue derived from rheumatoid arthritis and osteoarthritis patients
    Lars C Huber
    Center of Experimental Rheumatology, University Hospital Zurich, and Zurich Center of Integrative Human Physiology, Zurich, Switzerland
    Arthritis Rheum 56:1087-93. 2007
  5. ncbi The role of membrane lipids in the induction of macrophage apoptosis by microparticles
    Lars C Huber
    Center of Experimental Rheumatology, University Hospital Zurich, Gloriastrasse 23, CH 8091, Zurich, Switzerland
    Apoptosis 12:363-74. 2007
  6. ncbi Epigenetics in inflammatory rheumatic diseases
    Lars C Huber
    University Hospital Zurich, Zurich Center for Integrative Human Physiology, Zurich, Switzerland
    Arthritis Rheum 56:3523-31. 2007
  7. ncbi Antisense strategies in degenerative joint diseases: sense or nonsense?
    Lars C Huber
    Center of Experimental Rheumatology, WHO Collaborating Center for Molecular Biology and Novel Therapeutic Strategies for Rheumatic Diseases, University of Zurich, University Hospital Zurich, Gloriastr 23, CH 8091 Zurich, Switzerland
    Adv Drug Deliv Rev 58:285-99. 2006
  8. ncbi Synovial fibroblasts: key players in rheumatoid arthritis
    L C Huber
    Center of Experimental Rheumatology, University Hospital Zurich, Gloriastrasse 23CH 8091 Zürich, Switzerland
    Rheumatology (Oxford) 45:669-75. 2006
  9. ncbi The release of microparticles by apoptotic cells and their effects on macrophages
    J H W Distler
    Center of Experimental Rheumatology, Department of Rheumatology, University Hospital Zurich, Zurich, CH-8091, Switzerland
    Apoptosis 10:731-41. 2005
  10. ncbi Histone deacetylase 7, a potential target for the antifibrotic treatment of systemic sclerosis
    Hossein Hemmatazad
    Center of Experimental Rheumatology, University Hospital Zurich, Zurich, Switzerland
    Arthritis Rheum 60:1519-29. 2009

Detail Information

Publications21

  1. ncbi Trichostatin A prevents the accumulation of extracellular matrix in a mouse model of bleomycin-induced skin fibrosis
    Lars C Huber
    Center of Experimental Rheumatism, University Hospital Zurich, Gloriastrasse 25, 8091 Zurich, Switzerland
    Arthritis Rheum 56:2755-64. 2007
    ..In this study, we investigated the antifibrogenic effects of the histone deacetylase inhibitor trichostatin A (TSA) on cytokine-driven fibrotic responses in vitro and in vivo...
  2. ncbi Peripheral blood B lymphocytes derived from patients with idiopathic pulmonary arterial hypertension express a different RNA pattern compared with healthy controls: a cross sectional study
    Silvia Ulrich
    Department of Internal Medicine, Pulmonary Hypertension Clinic, University Hospital of Zurich, Zurich, Switzerland
    Respir Res 9:20. 2008
    ..The purpose of the present work was therefore to comparatively analyze peripheral blood B lymphocyte RNA expression characteristics in IPAH and healthy controls...
  3. ncbi Effects of a novel tyrosine kinase inhibitor in rheumatoid arthritis synovial fibroblasts
    L C Huber
    Center of Experimental Rheumatology, University Hospital Zurich, Gloriastrasse 25, CH 8091 Zurich, Switzerland
    Ann Rheum Dis 67:389-94. 2008
    ..In the present study, we investigated the effects of GW282974, a novel compound directed against tyrosine kinase activity with respect to the potential suppression of inflammation and destruction...
  4. ncbi Histone deacetylase/acetylase activity in total synovial tissue derived from rheumatoid arthritis and osteoarthritis patients
    Lars C Huber
    Center of Experimental Rheumatology, University Hospital Zurich, and Zurich Center of Integrative Human Physiology, Zurich, Switzerland
    Arthritis Rheum 56:1087-93. 2007
    ..We undertook this study to investigate the balance of histone acetylase and HDA activity in synovial tissue from RA patients compared with that from patients with osteoarthritis (OA) and normal controls...
  5. ncbi The role of membrane lipids in the induction of macrophage apoptosis by microparticles
    Lars C Huber
    Center of Experimental Rheumatology, University Hospital Zurich, Gloriastrasse 23, CH 8091, Zurich, Switzerland
    Apoptosis 12:363-74. 2007
    ....
  6. ncbi Epigenetics in inflammatory rheumatic diseases
    Lars C Huber
    University Hospital Zurich, Zurich Center for Integrative Human Physiology, Zurich, Switzerland
    Arthritis Rheum 56:3523-31. 2007
  7. ncbi Antisense strategies in degenerative joint diseases: sense or nonsense?
    Lars C Huber
    Center of Experimental Rheumatology, WHO Collaborating Center for Molecular Biology and Novel Therapeutic Strategies for Rheumatic Diseases, University of Zurich, University Hospital Zurich, Gloriastr 23, CH 8091 Zurich, Switzerland
    Adv Drug Deliv Rev 58:285-99. 2006
    ..To introduce these therapies in clinical practice, however, several hurdles still have to be overcome...
  8. ncbi Synovial fibroblasts: key players in rheumatoid arthritis
    L C Huber
    Center of Experimental Rheumatology, University Hospital Zurich, Gloriastrasse 23CH 8091 Zürich, Switzerland
    Rheumatology (Oxford) 45:669-75. 2006
    ..As a consequence, RASFs are no longer considered passive bystanders but active players in the complex intercellular network of RA...
  9. ncbi The release of microparticles by apoptotic cells and their effects on macrophages
    J H W Distler
    Center of Experimental Rheumatology, Department of Rheumatology, University Hospital Zurich, Zurich, CH-8091, Switzerland
    Apoptosis 10:731-41. 2005
    ..The release of microparticles from apoptotic cells may therefore represent a novel amplification loop of cell death...
  10. ncbi Histone deacetylase 7, a potential target for the antifibrotic treatment of systemic sclerosis
    Hossein Hemmatazad
    Center of Experimental Rheumatology, University Hospital Zurich, Zurich, Switzerland
    Arthritis Rheum 60:1519-29. 2009
    ..The purpose of this study was to analyze the silencing of histone deacetylase 7 (HDAC-7) as a possible mechanism by which TSA exerts its antifibrotic function...
  11. ncbi Inhibition of fibroblast activation protein and dipeptidylpeptidase 4 increases cartilage invasion by rheumatoid arthritis synovial fibroblasts
    Caroline Ospelt
    University Hospital, Zurich, Switzerland
    Arthritis Rheum 62:1224-35. 2010
    ....
  12. ncbi The induction of matrix metalloproteinase and cytokine expression in synovial fibroblasts stimulated with immune cell microparticles
    Jörg H W Distler
    Center of Experimental Rheumatology, Department of Rheumatology, University Hospital Zurich, CH 8091 Zurich, Switzerland
    Proc Natl Acad Sci U S A 102:2892-7. 2005
    ..These data provide evidence for a novel mechanism by which vesicles derived from activated or apoptotic immune cells can promote the destructive activity of synovial fibroblasts in rheumatoid arthritis...
  13. ncbi Insufficient medication documentation at hospital admission of cardiac patients: a challenge for medication reconciliation
    Pascal Frei
    Division of Gastroenterology and Hepatology, Department of Internal Medicine, University Hospital Zurich, Zurich, Switzerland
    J Cardiovasc Pharmacol 54:497-501. 2009
    ..Medication errors may occur when hospital doctors are not adequately informed about a patient's prescribed drugs...
  14. ncbi Platelet serotonin content and transpulmonary platelet serotonin gradient in patients with pulmonary hypertension
    Silvia Ulrich
    Department of Medicine and Pulmonology, Clinic and Policlinic of Internal Medicine, University Hospital of Zurich, Zurich, Switzerland
    Respiration 81:211-6. 2011
    ..Objective: To comparatively analyze plasmatic and intrathrombocytic serotonin levels in arterial and mixed venous blood of patients with PH and unaffected controls to elucidate pulmonary serotonin metabolisms...
  15. ncbi Microparticles stimulate the synthesis of prostaglandin E(2) via induction of cyclooxygenase 2 and microsomal prostaglandin E synthase 1
    Astrid Jungel
    Zurich Center of Integrative Human Physiology, and University Hospital Zurich, Zurich, Switzerland
    Arthritis Rheum 56:3564-74. 2007
    ..The goal of these studies was to elucidate the mechanisms by which microparticles activate synovial fibroblasts to express a proinflammatory phenotype...
  16. ncbi Gene targeting: roadmap to future therapies
    Lars C Huber
    WHO Collaborating Center for Molecular Biology and Novel Therapeutic Strategies, Department of Rheumatology, University Hospital, Gloriastrasse 25, CH-8091 Zurich, Switzerland
    Curr Rheumatol Rep 6:323-5. 2004
  17. ncbi The relationship between plasma microparticles and disease manifestations in patients with systemic sclerosis
    Serena Guiducci
    University Hospital Zurich, Zurich, Switzerland
    Arthritis Rheum 58:2845-53. 2008
    ..The aim of the present study was to analyze the profile of microparticles in the blood of patients with systemic sclerosis (SSc; scleroderma) and healthy controls...
  18. ncbi Imatinib mesylate reduces production of extracellular matrix and prevents development of experimental dermal fibrosis
    Jörg H W Distler
    University of Erlangen Nuremberg, Erlangen, Germany
    Arthritis Rheum 56:311-22. 2007
    ..This study was undertaken to test the potential use of imatinib mesylate as an antifibrotic drug for the treatment of dermal fibrosis in systemic sclerosis (SSc)...
  19. ncbi [Molecular pathways in aseptic loosening of orthopaedic endoprosthesis]
    Philipp Drees
    Orthopädische Klinik und Poliklinik der Johannes Gutenberg Universität, Mainz, Deutschland
    Biomed Tech (Berl) 53:93-103. 2008
    ..In this article, we review the molecular mechanisms and signal pathways that were unravelled as responsible factors for loosening orthopaedic implants. Finally, we discuss possible novel strategies for future therapeutic approaches...
  20. ncbi Microparticles as mediators of cellular cross-talk in inflammatory disease
    Jörg H W Distler
    Department of Internal Medicine 3, University of Erlangen, Erlangen, Germany
    Autoimmunity 39:683-90. 2006
    ..Together, these findings point to novel signaling pathways of cellular cross-talk that may operate along the spectrum of soluble cytokines and mediators of direct cell-cell contact...
  21. ncbi Microparticles as regulators of inflammation: novel players of cellular crosstalk in the rheumatic diseases
    Jörg H W Distler
    Institute for Clinical Immunology and Rheumatology, Dept of Internal Medicine III, University of Erlangen Nuremberg, Krankenhausstrasse 12, D 91054 Erlangen, Germany
    Arthritis Rheum 52:3337-48. 2005